Bisquaternary pyridinium oximes: Comparison of in vitro reactivation potency of compounds bearing aliphatic linkers and heteroaromatic linkers for paraoxon-inhibited electric eel and recombinant human acetylcholinesterase

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 2, 2010, Pages 787-794

  Bharate, Sandip B ^a   Guo, Lilu ^b   Reeves, Tony E ^c   Cerasoli, Douglas M ^c   Thompson, Charles M ^a,b  

^a UNIVERSITY OF MONTANA   (United States)

^b ATERIS Technologies LLC   (United States)

^c USAMRICD   (United States)

Author keywords

Acetylcholinesterase; Bisquaternary oximes; Organophosphorus; Paraoxon; Reactivation

Indexed keywords

2,2' BIS(HYDROXYIMINOMETHYL) 1,1' (2,5 FURANDIYLDIMETHYLENE)BISPYRIDINIUM DIBROMIDE; 2,2' BIS(HYDROXYIMINOMETHYL) 1,1' (2,5 THIOPHENEDIYLDIMETHYLENE)BISPYRIDINIUM DICHLORIDE; 2,2' BIS(HYDROXYIMINOMETHYL) 1,1' (3,5 ISOXAZOLDIYLDIMETHYLENE)BISPYRIDINIUM DIBROMIDE; 3 (HYDROXYIMINOMETHYL) 4' (CARBAMOYL) 1,10 (2,5 THIOPHENEDIYLDIMETHYLENE)BISPYRIDINIUM DICHLORIDE; 3,3' BIS(HYDROXYIMINOMETHYL) 1,1' (2,5 THIOPHENEDIYLDIMETHYLENE)BISPYRIDINIUM DICHLORIDE; 3,3' BIS(HYDROXYIMINOMETHYL) 1,1' (3,5 ISOXAZOLDIYLDIMETHYLENE)BISPYRIDINIUM DIBROMIDE; 3,3' BIS(HYDROXYIMINOMETHYL) 1,10 (2,5 FURANDIYLDIMETHYLENE)BISPYRIDINIUM DIBROMIDE; 4 (HYDROXYIMINOMETHYL) 4' (CARBAMOYL) 1,1' (2,5 THIOPHENEDIYL DIMETHYLENE)BISPYRIDINIUM DICHLORIDE; 4,4' BIS(CARBAMOYL) 1,1' (2,5 FURANDIYLDIMETHYLENE)BISPYRIDINIUM DIBROMIDE; 4,4' BIS(HYDROXYIMINOMETHYL) 1,1' (2,5 FURANDIYLDIMETHYLENE)BISPYRIDINIUM DIBROMIDE; 4,4' BIS(HYDROXYIMINOMETHYL) 1,1' (2,5 THIOPHENEDIYLDIMETHYLENE)BISPYRIDINIUM DICHLORIDE; 4,4' BIS(HYDROXYIMINOMETHYL) 1,1' (3,5 ISOXAZOLDIYLDIMETHYLENE)BISPYRIDINIUM DIBROMIDE; ACETYLCHOLINESTERASE; ALIPHATIC COMPOUND; ENZYME ACTIVATOR; FURAN DERIVATIVE; HETEROCYCLIC COMPOUND; OBIDOXIME; OXIME DERIVATIVE; PAROXYPROPIONE; PRALIDOXIME; PYRIDINIUM DERIVATIVE; RECOMBINANT ENZYME; THIOPHENE DERIVATIVE; TRIMEDOXIME; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EEL; ENZYME INHIBITION; ENZYME REACTIVATION; IN VITRO STUDY;

ACETYLCHOLINESTERASE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORUS; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; OXIMES; PARAOXON; PYRIDINIUM COMPOUNDS; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

ELECTROPHORUS ELECTRICUS;

EID: 76449113966     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.11.052     Document Type: Article

References (40)

1. Bajgar J. Adv. Clin. Chem. 38 (2004) 151
2. Taylor P., Radic Z., Hosca N.A., Camp S., Marchot P., and Berman H.A. Toxicol. Lett. 82-83 (1995) 453
3. Jokanovic M., and Stojiljkovic M.P. Eur. J. Pharmacol. 553 (2006) 10
4. Childs A.F., Davies D.R., Green A.L., and Rutland J.P. Br. J. Pharmacol. 10 (1955) 462
5. Wilson I.B., and Ginsburg S. Biochim. Biophys. Acta 18 (1955) 168
6. Poziomek E.J., Hackley B.E.J., and Steinberg G.M. J. Org. Chem. 23 (1958) 714
7. Hobbiger F., O'Sullivan D.G., and Sadler P.W. Nature 182 (1958) 1498
8. Luttringhaus A., and Hagedorn I. Arzneimittelforschung 14 (1964) 1
9. Erdmann W.D., and Clarmann M.v. Dtsch. Med. Wochenschr. 88 (1963) 2201
10. Hagedorn I., Gündel W.H., and Schoene K. Arzneimittelforschung 19 (1969) 603
11. Oldiges H., and Schoene K. Arch. Toxicol. 26 (1970) 293
12. Inns R.H., and Leadbeater L. J. Pharm. Pharmacol. 35 (1983) 427
13. Musilek K., Holas O., Jun D., Dohnal V., Gunn-Moore F., Opletalova V., Dolezal M., and Kuca K. Bioorg. Med. Chem. 15 (2007) 6733
14. Musilek K., Holas O., Kuca K., Jun D., Dohnal V., Opletalova V., and Dolezal M. Bioorg. Med. Chem. Lett. 17 (2007) 3172
15. Kim T.H., Kuca K., Jun D., and Jung Y.S. Bioorg. Med. Chem. Lett. 15 (2005) 2914
16. Oh K.A., Yang G.Y., Jun D., Kuca K., and Jung Y.S. Bioorg. Med. Chem. Lett. 16 (2006) 4852
17. Yang G.Y., Oh K.A., Park N.J., and Jung Y.S. Bioorg. Med. Chem. 15 (2007) 7704
18. Musilek K., Holas O., Kuca K., Jun D., Dohnal V., and Dolezal M. J. Enzyme Inhib. Med. Chem. 22 (2007) 425
19. Kassa J. J. Toxicol. Clin. Toxicol. 40 (2002) 803
20. Worek F., Reiter G., Eyer P., and Szinicz L. Arch. Toxicol. 76 (2002) 523
21. Clement J.G., and Erhardt N. Arch. Toxicol. 68 (1994) 648
22. Berry W.K. Biochem. Pharmacol. 20 (1971) 1333
23. Yousefpour M., Bahrami F., behboodi B.S., Khoshbaten A., and Asgari A. Toxicology 217 (2006) 221
24. Bharate S.B., Guo L., Reeves T.E., Cerasoli D.M., and Thompson C.M. Bioorg. Med. Chem. Lett. 19 (2009) 5101
25. Hagedorn I., Stark I., Schoene K., and Schenkel H. Arzneimittelforscung 28 (1978) 2055
26. Kuca K., Bielavsky J., Cabal J., and Bielavska M. Tetrahedron Lett. 44 (2003) 3123
27. Kuca K., Bielavsky J., Cabal J., and Kassa J. Bioorg. Med. Chem. Lett. 13 (2003) 3545
28. Kuca K., Cabal J., Patocka J., and Kassa J. Lett. Org. Chem. 1 (2004) 84
29. Musilek K., Lipka L., Racakova V., Kuca K., Jun D., Dohnal V., and Dolezal M. Chem. Pap. 60 (2006) 48
30. Sikder A.K., Ghosh A.K., and Jaiswal D.K. J. Pharm. Sci. 82 (1993) 258
31. Yang G.Y., Yoon J.H., Seong C.-M., Park N.S., and Jung Y.S. Bull. Korean Chem. Soc. 24 (2003) 1
32. Ellman G.L., Courtney K.D., Andres V.J., and Feather-Stone R.M. Biochem. Pharmacol. 7 (1961) 88
33. Musilek K., Kuca K., Jun D., Dohnal V., and Dolezal M. Bioorg. Med. Chem. Lett. 16 (2006) 622
34. Tattersall J.E. Br. J. Pharmacol. 108 (1993) 1006
35. Bharate S.B., and Thompson C.M. Chem. Biol. Drug Des. (2009) Communicated
36. Thompson C.M., Ryu S., and Berkman C.E. J. Am. Chem. Soc. 114 (1992) 10710
37. Worek F., Thiermann H., Szinicz L., and Eyer P. Biochem. Pharmacol. 68 (2004) 2237
38. Kryger G., Harel M., Giles K., Toker L., Velan B., Lazar A., Kronman C., Barak D., Ariel N., Shafferman A., Silman I., and Sussman J.L. Acta Crystallogr., Sect. D 56 (2000) 1385
39. Bourne Y., Grassi J., Bougis P.E., and Marchot P. J. Biol. Chem. 274 (1999) 30370
40. Ghanem E., Li Y., Xu C., and Raushel F.M. Biochemistry 46 (2007) 9032